173 related articles for article (PubMed ID: 8769198)
21. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
22. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
23. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
Warrens AN; Salama A; Waters JB; Lechler RI
Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
[No Abstract] [Full Text] [Related]
24. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
[No Abstract] [Full Text] [Related]
25. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
26. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
[No Abstract] [Full Text] [Related]
27. Use of Sandimmun Neoral in renal transplant patients. International Sandimmun Neoral Study Group.
Frei U; Taesch S; Niese D
Transplant Proc; 1994 Oct; 26(5):2928-31. PubMed ID: 7940925
[No Abstract] [Full Text] [Related]
28. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
[No Abstract] [Full Text] [Related]
29. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
[No Abstract] [Full Text] [Related]
30. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.
Keown PA
Transplant Proc; 1996 Aug; 28(4):2147-50. PubMed ID: 8769183
[TBL] [Abstract][Full Text] [Related]
31. Changing stable heart transplant recipients from Sandimmune to Neoral.
Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
[No Abstract] [Full Text] [Related]
32. Case reports on conversion to Neoral therapy in renal transplant patients.
Curtis JJ
Transplant Proc; 1996 Aug; 28(4):2221-2; discussion 2218. PubMed ID: 8769205
[No Abstract] [Full Text] [Related]
33. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group.
Grant D; Rochon J; Levy G
Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208
[No Abstract] [Full Text] [Related]
34. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
[No Abstract] [Full Text] [Related]
35. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR
Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128
[No Abstract] [Full Text] [Related]
36. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
[No Abstract] [Full Text] [Related]
37. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
38. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
[No Abstract] [Full Text] [Related]
39. Case study: de novo application of Neoral in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
[No Abstract] [Full Text] [Related]
40. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
